Thread by @M_SuarezCalvet

🚨 Our paper on p-tau231 and p-tau217 as blood 🩸biomarkers 🧪 in preclinical #Alzheimers 🧠 is now published in @NatureMedicine

nature.com/articles/s4159…

@goteborgsuni #BarcelonaBeta @fpmaragall
@hospitaldelmar @IMIM_research @KingsCollegeLon

🧵 summary
👇🏾

(1/6)

We investigated 6 blood 🩸 biomarkers in 397 cognitively unimpaired individuals of the ALFA study at #BarcelonaBeta :

🟤 p-tau181
🟣 p-tau217
🟠 p-tau231
🟢 GFAP
🔵 NfL
🔴 Abeta42/40

and all were significantly increased in preclinical #Alzheimers

but ..

(2/6)

Plasma 🩸 p-tau231 🟠 and p-tau217 🟣 had:

👉🏾 the highest increase with the lowest #amyloid burden

👉🏽 the strongest association with amyloid PET

👉🏿 a significant association with longitudinal increases in amyloid PET uptake

(3/6)

Higher plasma 🩸 p-tau231 🟠 was associated with cognitive decline in amyloid-positive cognitively unimpaired individuals

(4/6)

Plasma biomarkers will facilitate recruitment of participants at high risk of #Alzheimer for clinical trials

✅ Choice of 🩸 biomarker may depend on the goal of the trial
✅Need to confirm in independent and diverse cohorts
✅CSF/PET still needed for confirmation

(5/6)

Thanks to everyone who made this possible!

🙏🏿 A great group of scientists
@NicholasAshton @Marta_Mila_ @JuandoGispert @andrealessa @age_armand @gesalbla @TommyKakari @GSBenavides @CarolinaMingui2 @Jeff_Neuro Zetterberg Blennow and many more!

🙏🏼 ALFA participants 💚

(6/6)

And @MehrnazShekari !!! 💚